501
1735584226014562112172
Ces36987936014570127174
Urol38977936014578115180208
2022;41307936014562121178238261
26(3):44177936014561119152210239261
165–17347037936014562116175236289340399
PŘEHLEDOVÉ3674207016974156235334409485586692777855
ČLÁNKY4568207016989162260360444533
5.62489601335677
Kobayashi725896013361119182235284337380440465
H,121489601337396
Carrasquillo1333896013365118153189242285346406431456481542
JA,1898896013342106131
Paik2052896013360111136187
CH,2262896013365136159
Waldmann2444896013394145170232323375436496
TA,2963896013356116140
Tagaya3127896013355101162214264317
Y.346789601336176
Differences356689801317295124154206237289347395446486
of407789801315988
biodistribution,418989801316284142202224263298329352411470503525583641659
phar‑4873898013162120169200229
macokinetics,6241048013190139188244290314371424457479528569588
and12361048013150108167
tumor1427104801313492181239271
targeting1722104801313484115173226259281339398
between21441048013161115148230282336393
interleukins2562104801312380112163194217270327373397454494
230801048013153
and31571048013150108168
153349104801315398
Cancer34881048013163112170219270301
Res38131048013156109149
2000;40061048013153105160215233
60(13):42631048013154108137184229254270
3577–8345571048013154104154206255310362
6.624119601335679
ImmunityBio.7271196013324116207266327352388442502527587608
141359119801315299
215001198013152
2022,15941198013152104153206223
ImmunityBio18411198013122111200257315337370421477499556
Announces24211198013163121179237295353402453493
Over29381198013172123175206
2431681198013153100
Months32931198013184142201232290330
Median36471198013184137198219268325
Duration39961198013170129160210242264322380
of4400119801315786
Complete45101198013161117207267290342376427
Re‑49611198013154107142
mission,6241348013190112151191212270328346
with9941348013178100134192
100%1210134801315198153235
NMIBC14691348013168153175229292
CIS1785134801316082130
Patient19401348013153101133155208265297
Survival,22611348013149106137190213262312334352
Setting26371348013149102135171194251310
a29721348013147
New30431348013169122200
‘Magnitude32671348013117102151211268290323381441493
of3785134801315684
Benefit’38931348013154107165218244271304325
in4243134801312078
Patients43451348013153101133156208266298339
with4709134801317799133191
BCG49241348013153116179
Unresponsive6241498013169126157209249308367426465487536588
Bladder1236149801316386134194253306337
Cancer15981498013170119177226277308
(online)1930149801313792150172194251304330
Dostupné22991498013178137177212269329387440
z:2764149801315171
https://immunitybio2859149801316799135195235253293323346435524581639661694745806828886
com/immunitybio‑announces­376214980131491051942342573464354925505716056567177397978328819389961054111211701219127013101341
‑over-24-months‑median‑duration‑of‑complete‑remission‑with-100-%NBIMC‑CIS62416480131339314219322525430034838247353159062167971975084089395497510241081111511771234126513151347136914271485151915791608163816891745183518941917197020032054208921222173226222842323236323842442250025342613263626692727276128072854290929453026309531493172325733183337340334243473
7.624179601335668
Alsaab7151796013375101143197249311
HO,10491796013380156176
Sau12481796013362115175
S,1446179601336285
Alzhrani15541796013375101147208243296357382
R,1959179601336792
et2074179601336399
al.2197179601336186108
PD-123291798013163132168214
and25671798013158116176
PD‑L127671798013163132167218262
Checkpoint30531798013171129182231277338398420478510
Signaling3587179801315980139197246268289347407
Inhibition4018179801313189146168228250284306364422
for4464179801313794126
Cancer46151798013170120178227277309
Im‑49481798013131120154
munotherapy:6241948013190147205263296354407438488548595614
Mechanism,12621948013186139189246295353375414502520
Combinations,18061948013163119209268291348397429451509568607626
and24561948013150107167
Clinical2647194801316385106164185234283306
Outcome29771948013173132165212268357410
Frontiers3429194801315079136194226248301332373
in3826194801312381
pharmacology39311948013160119168199289338387442466524584632
2017;46011948013154105153197210
8:4835194801315371
56149301948013154105151
8.624209601335680
Kumar7272096013360118209262297
V,1048209601336177
Chaudhary11482096013364124176236298358411446501
N,1672209601337396
Garg17912096013371125160221
M,20352096013389113
et2171209601335591
al.2286209601335378101
Corrigendum:24102098013163119151183206265318376435492581598
Current30322098013163118150182234291323
Diagnosis3379209801317294142202260318358379418
and38212098013150108167
Management40122098013186135193242301354443496554586
of4622209801315987
Immune47332098013124112201259316369
Related6242248013156109131180212263323
Adverse9712248013163122171223254295348
Events1343224801315098150208240281
(irAEs)164822480131285081139189231255
Induced1927224801312280139196245296356
by23072248013159107
Immune24382248013122110199256314367
Checkpoint28292248013162119172222267329388410468500
Inhibitor3353224801312179137159218241274330362
Therapy37392248013150110163194244304351
Frontiers4127224801315078135193225247300331372
in4523224801312279
pharmaco‑46262248013160118167198288337386442477
logy624239801312381142190
2017;8522398013153105153196209
8:1085239801315471
31111812398013153100140
9.624254601335675
Le7232546013356110
DT,8572546013378130146
Durham10262546013378139174235287378
JN,14282546013345117140
Smith15922546013358149174210270
KN,18862546013364137160
et2069254601336096
al.2189254601335783105
Mismatch23182548013190113152240289321367425
repair2767254801313789149198220251
deficiency30432548013164117143169218239292350399449
predicts3517254801316597148209231279315357
response3898254801313788129188247305345398
of4320254801316392
solid44362548013145104127148207
tumors4667254801313997186244276317
to5008254801313995
PD-16242698013155124160206
blockade854269801316184142191236287347400
Science12952698013151100121174232280331
2017;16682698013153105153196209
357(6349):19012698013154104154178228279333383409425
409–1323502698013154109162219266310
10.6242846013356107129
Thana7762846013360122174234287
M,10862846013393117
Wood12272846013398155216279
L.1529284601335781
Immune16342848013128117206263321374
checkpoint20322848013155112165215260322381403461493
inhibitors2549284801312885143165224247280336368409
in2982284801312886
genitourinary30922848013165118176198231287345376399456505536588
malignancies37042848013195144166188247305354411460482534574
Current43222848013168124155187239297328
onkology46742848013164123168225248306366415
2020;6242998013154105155206225
27(Suppl8732998013153103127174231291351374
2):128929980131548097
S69–S7714102998013151105156213259310362
11.6243146013357101118
Mondal7663146013396157218280332358
M,11473146013396120
Guo12913146013379139200
J,1514314601334970
He16073146013380135
P,1766314601336675
et1865314601336399
al.1987314601336187109
Recent21203148013164117167218276307
advances24523148013158117167217274323374414
of2891314801316695
oncolytic30103148013166125174230253301338361409
virus3443314801315881112170210
in3677314801313188
cancer37903148013157107164213264296
therapy41103148013142100153185235294342
Human44903148013177135224273331
vacci‑48453148013158107156203225258
nes6243298013159112152
&8003298013157
immunotherapeutics8813298013118107196253311369401459512544594653707765798820868910
2020;18353298013153105155206224
16(10):20843298013153100128175222249266
2389–40223743298013154107159211268324379428
12.6243446013357105128
Razzaghdoust7753446013367120167217272333394456516577619656
A,14553446013375100
Rahmatizadeh15783446013367120181272325360385432486548603664
S,2266344601336285
Mofid23743446013396157186215277
B,2674344601336890
et27873446013363100
al.2910344601336187109
Data‑Driven30433448013179128161210244316349371421473531
Discovery35983448013179102141190246294346378430
of4052344801316795
Molecular41713448013194153176229278336358407438
Targets46333448013160101133191244277319
for4976344801313794126
Antibody‑Drug6243598013164122154176236295355404436508541599658
Conjugates13063598013163119178199256316364397448488
in1818359801312380
Cancer19233598013162112170218269301
Treatment2248359801315175127175207297350408439
BioMed2731359801315577135220273334
research3089359801313284124177225256303361
international3474359801312381112163195253302334356414473521544
2021;40603598013154105155202213
2021:42973598013153105154202213
267057345343598013153104154204255305357
13.6243746013356105126
Rosenberg7743746013360120162217278340396431492
SA,12903746013355120145
Restifo14583746013360115158195220252312
NP.17933746013373132141
Adoptive19583748013165123182242275297346398
cell23803748013150101123145
transfer2549374801313566116174213243295327
as2900374801315090
personalized30143748013162116147188246305353376397441492553
immunotherapy35913748013124112201258316374407465518549599659706
for4321374801312987119
human44643748013159117205254312
cancer48003748013150100157206257288
Science6243898013151100122174232281332
2015;9973898013153105153197212
348(6230):12333898013154108163191241291344396423440
62–816973898013153104156211
14.6244046013356106128
Perera7754046013357110145200235288
MPJ,10874046013386144176197
Thomas13074046013353114174266318361
PB,16914046013357114137
Risbridger1851404601335783126187223249310372427462
GP,23374046013369127137
et2497404601335389
al.261040460133517698
Chimeric27324048013161118140228282313336384
Antigen31404048013162120152174233286344
Receptor35084048013153106156207267299355387
T‑Cell3919404801314976142193215237
Therapy41804048013149109162194243303350
in4554404801312179
Metastatic46574048013183136169219259293343375397445
Castrate‑Resistant6244198013163112152187218268301352386443496536557596631680738770
Prostate1418419801315586142182217267299350
Cancer17924198013162112170219269301
Cancers21314198013163112170219270301342
2022;25174198013153105154207225
14(3)27664198013153100129179204
15.6244346013356105126
Madan7734346013385137199251312
RA,11084346013355124149
Antonarakis12804346013364124159218278330366418469496538
ES,18414346013351105127
Drake19924346013369105158209262
CG,22774346013360127151
et2451434601335188
al.256243460133497497
Putting26824348013151108141177199257316
the3022434801313088141
Pieces3187434801315172125174225265
Together:3476434801314798158211244302355386406
Completing39054348013159115205264287340373395452511
the4440434801313088141
Mechanism46054348013182135184242291348370409497
of624449801315987
Action7354498013164112148170228286
Jigsaw1045449801313860119158208286
for1355449801312986118
Sipuleucel‑T1497449801315172132190212265322371422444477522
Journal2056449801313896154185244293315
of2395449801315987
the2506449801313492145
National26754498013171119152174231290339361
Cancer30604498013163112170219270301
Institute3385449801312381120155177210268302353
2020;37794498013153105155206224
112(6):4028449801315394139164214240257
562–7343094498013154106156208255307
16.6244646013356107130
Vogelzang7774646013366122184239265311366426487
NJ,12884646013377118139
Beer14504646013365120176211
TM,16854646013359147171
Gerritsen18794646013376132168203229265309364425
W,23274646013398116
et2466464601336096
al.2586464601335883105
Efficacy2715464801315682110138187237285336
and30754648013155113173
Safety32724648013156106133186219270
of3566464801316492
Autologous36824648013169126159215238296356415472512
Dendritic42184648013176130188247278301334356405
Cell‑Based46474648013168119141163196252302342395455
Immunotherapy,6244798013123112201258316374407465518549599659706719
Docetaxel,13674798013176135184235268318366417440457
and18484798013155113172
Prednisone2044479801316191142203261282321379438491
vs2559479801315595
Placebo2678479801316082130179230289349
in3051479801312885
Patients31604798013160108141163215273305347
With35314798013195118152210
Metastatic37654798013190144177226266301350382404453
Castration‑Resistant42424798013167117157191223273305327385444477533586627648687722771829861
Prostate624494801315586142182217266299350
Cancer:9984948013162112170218269301321
The13434948013151111164
VIABLE1531494801315680142197245296
Phase18514948013155112160200253
321284948013154
Randomized22064948013156105163222280370392436487547
Clinical2778494801316284106163185233283305
Trial310749480131517699147169
JAMA3319494801313898184248
onkology35914948013158117162219242300360409
202240374948013154106155208
17.6245096013356104115
Sartor7625096013351104139178237273
O,1059509601337291
de11745096013358113
Bono13105096013357117178238
J,1571509601333859
Chi16535096013360120145
KN,18215096013356130153
et1997509601335288
al.210850960133507598
Lutetium-177-PSMA-617222950980131461021351862192422983874214675115635906466967798438759329771021
for3274509801312582114
Metastatic34125098013182135168218258292342374396444
Castration‑Resistant38805098013159109149183215265297319377435469525578619640679713763821853
Prostate4757509801315182138178213262294345
Cancer6245248013163112170219270301
The9635248013151111164
New11515248013171124202
England13775248013152109168190239297356
journal1757524801312482140171230278301
of2082524801315887
medicine21935248013190143203225273295353406
2021;26405248013154105155202212
385(12):28775248013153105157182230275301317
1091–10332185248013154101155203252298345395
18.6245396013356106129
Schulz776539601335099158217242288
GB,10875396013367126148
Black1258539601335681133181231
PC.15125396013355118142
Combination16775398013158114203262284341389421443500558
therapies2259539801313087140171220279301353393
involving2676539801311976122179201250272329388
checkpoint‑inhibitors30885398013145102155204248309368390447478507530587644665724746779834866907
for4018539801312582113
treatment4155539801313061112160192280333390421
of4600539801315583
urothelial4706539801315485141173231283305327374396
carcinoma:624554801314999130177199256314404453470
a11185548013150
narrative11925548013159108139171221254276325377
review1593554801313284133155208286
Translational1918554801315176126184223245294326348406464513535
andrology24775548013150108167199255278336397445
and29465548013150108167
urology3137554801315990147170228288336
2021;35115548013154105155202212
10(10):37485548013153100129177224251268
4014–2140405548013153108156202259306353
19.6245696013356106125
Kwon7725696013364141201261
WA,10575696013397160185
Seo12655696013358114175
HK.14635696013376135161
Emerging16485698013156144198229287309366426
agents20985698013154114166224256298
for2420569801313390122
the2567569801313896149
treatment2740569801313970122170202292345403434
of3199569801316391
metastatic33145698013195148181231270305354387409457
urothelial3795569801316394151183241294317338387409
cancer42285698013153103161210260292
Investigative4558569801312885133184225259281340389421443493544
and6245848013150108167
clinical81558480131497193150172220270292
urology1131584801315990147170228288337
2021;15055848013154105155202213
62(3):17425848013153104129180204221
243–5519875848013154102151206257306
20.6245996013356111133
Powles7805996013366124204229284327
T,1131599601336177
Rosenberg12325996013366126169224285346402438499
JE,17545996013348102124
Sonpavde19025996013361122182244297348409463
GP,23895996013378137146
et2558599601336399
al.2680599601336086108
Enfortumab28125998013159116144201233270328417465525
Vedotin33615998013164113173231264286343
in3728599801313188
Previously3840599801316393145194217274332372393441
Treated4306599801315883134182214265326
Advanced46565998013171130179229287335386446
Urothelial6246148013169100156189247300322344392414
Carcinoma10626148013163113144191213270328418467
The15726148013151111164
New17606148013170124202
England19866148013151109168190239297356
journal2366614801312481139171229278300
of2691614801315886
medicine28026148013190143203225273295353406
2021;32496148013153105155202212
384(12):34856148013154106161190238282308325
1125–353834614801315495139192247296346
21.6246296013356107124
Bansal7716296013366120180222276301
A,1096629601337398
Singh1217629601336185146207267
J,1508629601334768
Kaur15996296013366120179215
S,1837629601336183
Kaur19446296013366119179214
N.21826296013378102
Enfortumab23076298013158115143200232269327416465524
Vedotin‑Induced28556298013163112173231263285343377401459518575624674735
Toxic36146298013158109154177225
Epidermal38636298013158117140199252283373422444
Necrolysis:43316298013177130180211268291339379401439457
A48126298013171
Rare49076298013162112143195
Fatal624644801315195127177199
Adverse8476448013164122172224255296349
Reaction12206448013156109157206242264322380
Indian1643644801312381140162211268
dermatology19356448013160113145234283315371395453513561
online25206448013159117140161219272
journal2816644801312381139170229278300
2022;31596448013153105154207225
13(1):3408644801315398124172192209
128–303641644801315398149205254306
22.6246596013357112135
Schmidinger7836596013362111171262288350375435497552587
M,13946596013396120
Resch15386596013367122165214275
I,1836659601333457
Fajkovic19166596013362110136187246297323372
H,23126596013379103
et2438659601336399
al.2561659601336186109
Dual26936598013180138187209
immune29266598013132120210267325378
check33286598013158115169218264
point36166598013169128151208240
blockade3880659801316992151200246297356409
or4314659801316698
immune44366598013132120210267325378
check48386598013158115169218264
point‑tyrosine6246748013161120142200232260294345378434474495553606
kinase1254674801315478135184224277
inhibitor1555674801313088146167227249283339371
combination:19506748013156112202261284341390422444502561578
as2552674801315797
a26736748013157
first‑line275467480131346192132167196220241299352
treatment3130674801314173124172205294347405437
in3591674801313088
metastatic37036748013197150183233273307357389411459
renal4186674801314092150198221
cell44316748013156107129151
carcinoma?46066748013157106138184206264322411460497
Current6246898013163118149182233291323
opinion9716898013158119141199220278337
in1332689801312380
urology1436689801315990147170228288336
2021;18106898013154105155202212
31(3):2047689801315399121172196213
270–522846898013154103153211263